Investment
Features
FeesSafety
Academy
More
Pluang+

Compare General Mills, Inc. (GIS) vs Eli Lilly And Co (LLY) Price & Performance

General Mills, Inc.Trade
Eli Lilly And CoTrade

Price performance (Past 24H)

Key statistics

General Mills, Inc. vs Eli Lilly And Co — how do they compare? General Mills, Inc. trades at $37.4 (market cap $20.24B), while Eli Lilly And Co trades at $1,205 (market cap $1.08T). The key difference: Eli Lilly And Co is far larger — about 53.4× General Mills, Inc.'s market cap, and General Mills, Inc. pays the higher dividend (6.43%). Which is the better fit depends on your goals.

GISLLY
Market Cap
$20.24B$1.08T
Sector
Consumer StaplesHealth
52-Week High
$51.11$1.24K
52-Week Low
$32.17$639.43
Enterprise Value
$33.73B$1.13T
Dividend Yield
6.43%0.57%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

General Mills, Inc.

General Mills (GIS) trades at $37.26, up 1.0% with a bullish technical signal. The stock shows mixed fundamentals with declining revenue ($19.49B in 2025) and negative net income margin (-0.48%), but maintains strong cash flow from operations ($2.92B). Recent earnings beat expectations in Q3 2025 and Q2 2026, while analyst sentiment remains cautious with 61% hold ratings. The company continues dividend payments and focuses on cost-saving initiatives.

Investment outlook remains balanced with attractive valuation (P/E 9.23) offset by margin pressures. Key opportunities include dividend yield and cost savings program, while risks involve declining profitability and competitive pressures. Wall Street consensus price target of $35.36 suggests limited upside from current levels.

Eli Lilly And Co

Eli Lilly (LLY) trades at $1,231.58, up 3.87% in the past 24 hours, reflecting strong momentum near its 52-week high. The stock exhibits bullish technical signals with robust fundamentals, including 48% revenue growth in Q2 2026 and a net income margin of 33.53%. Recent news highlights legal actions against black-market drug sales and positive analyst sentiment following earnings beats.

Outlook remains positive with a consensus price target of $1,380, though high valuation ratios (P/E 40.79) and regulatory risks pose challenges. Earnings growth and pipeline advancements, like retatrutide, drive upside potential, but investors should monitor competitive pressures and execution risks.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About General Mills, Inc.

General Mills is a leading global packaged food company that produces snacks, cereal, convenient meals, yogurt, dough, baking mixes and ingredients, pet food, and superpremium ice cream. Its largest brands are Nature Valley, Cheerios, Old El Paso, Yoplait, Pillsbury, Betty Crocker, BLUE, and Haagen-Dazs. In fiscal 2022, 77% of its revenue was derived from the United States, although the company also operates in Canada, Europe, Australia, Asia, and Latin America. While most of General Mills' products are sold through retail stores to consumers, the company also sells products into the food-service channel and the commercial baking industry.

Read more on GIS

About Eli Lilly And Co

Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer

Read more on LLY